These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37874242)

  • 1. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk.
    Xia T; Du M; Li H; Wang Y; Zha J; Wu T; Ju S
    Radiology; 2023 Oct; 309(1):e231007. PubMed ID: 37874242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
    Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.
    Fowler KJ; Venkatesh SK; Obuchowski N; Middleton MS; Chen J; Pepin K; Magnuson J; Brown KJ; Batakis D; Henderson WC; Shankar SS; Kamphaus TN; Pasek A; Calle RA; Sanyal AJ; Loomba R; Ehman R; Samir AE; Sirlin CB; Sherlock SP
    Radiology; 2023 Oct; 309(1):e231092. PubMed ID: 37815451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
    Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.
    Han A; Byra M; Heba E; Andre MP; Erdman JW; Loomba R; Sirlin CB; O'Brien WD
    Radiology; 2020 May; 295(2):342-350. PubMed ID: 32096706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Ajmera V; Park CC; Caussy C; Singh S; Hernandez C; Bettencourt R; Hooker J; Sy E; Behling C; Xu R; Middleton MS; Valasek MA; Faulkner C; Rizo E; Richards L; Sirlin CB; Loomba R
    Gastroenterology; 2018 Aug; 155(2):307-310.e2. PubMed ID: 29660324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
    Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
    Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes.
    Vu KN; Gilbert G; Chalut M; Chagnon M; Chartrand G; Tang A
    J Magn Reson Imaging; 2016 May; 43(5):1090-9. PubMed ID: 26536609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of liver fat in the UK Biobank cohort.
    Wilman HR; Kelly M; Garratt S; Matthews PM; Milanesi M; Herlihy A; Gyngell M; Neubauer S; Bell JD; Banerjee R; Thomas EL
    PLoS One; 2017; 12(2):e0172921. PubMed ID: 28241076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
    Jiang H; Chen HC; Lafata KJ; Bashir MR
    Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
    Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
    J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials.
    Nedrud MA; Chaudhry M; Middleton MS; Moylan CA; Lerebours R; Luo S; Farjat A; Guy C; Loomba R; Abdelmalek MF; Sirlin CB; Bashir MR
    Radiology; 2023 Mar; 306(3):e220743. PubMed ID: 36318027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.
    Jung J; Han A; Madamba E; Bettencourt R; Loomba RR; Boehringer AS; Andre MP; Erdman JW; O'Brien WD; Fowler KJ; Sirlin CB; Loomba R
    Radiology; 2022 Jul; 304(1):75-82. PubMed ID: 35348378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
    Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
    Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
    Mamidipalli A; Fowler KJ; Hamilton G; Wolfson T; Covarrubias Y; Tran C; Fazeli S; Wiens CN; McMillan A; Artz NS; Funk LM; Campos GM; Greenberg JA; Gamst A; Middleton MS; Schwimmer JB; Reeder SB; Sirlin CB
    Eur Radiol; 2020 Sep; 30(9):5120-5129. PubMed ID: 32318847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
    Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.